IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v33y2015i7p749-763.html
   My bibliography  Save this article

The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation

Author

Listed:
  • Anita Chawla
  • Ginger Carls
  • Edmund Deng
  • Edward Tuttle

Abstract

Regulatory policy and litigation risk both played a role in anti-obesity drug development; however, product revenue—reflecting efficacy at acceptable levels of safety—was by far the most important factor. To date, relatively modest sales associated with recent product introductions suggest that developing a product that is sufficiently efficacious with an acceptable level of safety continues to be the primary challenge in this market. Copyright Springer International Publishing Switzerland 2015

Suggested Citation

  • Anita Chawla & Ginger Carls & Edmund Deng & Edward Tuttle, 2015. "The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation," PharmacoEconomics, Springer, vol. 33(7), pages 749-763, July.
    • Handle: RePEc:spr:pharme:v:33:y:2015:i:7:p:749-763
    DOI: 10.1007/s40273-015-0300-0
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40273-015-0300-0
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s40273-015-0300-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.
    2. Light, Donald W. & Warburton, Rebecca N., 2005. "Setting the record straight in the reply by DiMasi, Hansen and Grabowski," Journal of Health Economics, Elsevier, vol. 24(5), pages 1045-1048, September.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Christian Frois & Pierre-Yves Cremieux, 2015. "For a Step Change to Curb the Obesity Epidemic," PharmacoEconomics, Springer, vol. 33(7), pages 613-617, July.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. G. Kent Fellows & Daniel J. Dutton & Aidan Hollis, 2018. "Making Sure Orphan Drugs Don’t Get Left Behind," SPP Communique, The School of Public Policy, University of Calgary, vol. 10(6), August.
    2. Makai, Peter & Brouwer, Werner B.F. & Koopmanschap, Marc A. & Stolk, Elly A. & Nieboer, Anna P., 2014. "Quality of life instruments for economic evaluations in health and social care for older people: A systematic review," Social Science & Medicine, Elsevier, vol. 102(C), pages 83-93.
    3. Pereira, Cristiano Gonçalves & Lavoie, Joao Ricardo & Garces, Edwin & Basso, Fernanda & Dabić, Marina & Porto, Geciane Silveira & Daim, Tugrul, 2019. "Forecasting of emerging therapeutic monoclonal antibodies patents based on a decision model," Technological Forecasting and Social Change, Elsevier, vol. 139(C), pages 185-199.
    4. Chen, Xu & Yang, Huan & Wang, Xiaojun, 2019. "Effects of price cap regulation on the pharmaceutical supply chain," Journal of Business Research, Elsevier, vol. 97(C), pages 281-290.
    5. Hyunju Rachel Kim, 2014. "Formulation of a Success Model in Pharmaceutical R&D," SAGE Open, , vol. 4(1), pages 21582440145, March.
    6. van Rijnsoever, Frank J. & Eveleens, Chris P., 2021. "Money Don't matter? How incubation experience affects start-up entrepreneurs' resource valuation," Technovation, Elsevier, vol. 106(C).
    7. Margaret K. Kyle & Anita M. McGahan, 2012. "Investments in Pharmaceuticals Before and After TRIPS," The Review of Economics and Statistics, MIT Press, vol. 94(4), pages 1157-1172, November.
    8. Feng Xie, 2018. "Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation," PharmacoEconomics, Springer, vol. 36(8), pages 883-888, August.
    9. Marijn A. Weele & Frank J. Rijnsoever & Menno Groen & Ellen H. M. Moors, 2020. "Gimme shelter? Heterogeneous preferences for tangible and intangible resources when choosing an incubator," The Journal of Technology Transfer, Springer, vol. 45(4), pages 984-1015, August.
    10. Vargas-Peláez, Claudia Marcela & Soares, Luciano & Rover, Marina Raijche Mattozo & Blatt, Carine Raquel & Mantel-Teeuwisse, Aukje & Rossi Buenaventura, Francisco Augusto & Restrepo, Luis Guillermo & L, 2017. "Towards a theoretical model on medicines as a health need," Social Science & Medicine, Elsevier, vol. 178(C), pages 167-174.
    11. Hollis, Aidan & Ahmed, Ziana, 2014. "The path of least resistance: Paying for antibiotics in non-human uses," Health Policy, Elsevier, vol. 118(2), pages 264-270.
    12. von Bandemer, Stephan & Merkel, Sebastian & Nimako-Doffour, Anna, 2012. "Medizinisch-technische Innovationen in der Gesundheitswirtschaft am Beispiel der Neuen Untersuchungs- und Behandlungsmethoden (NUB)," Forschung Aktuell 04/2012, Institut Arbeit und Technik (IAT), Westfälische Hochschule, University of Applied Sciences.
    13. Uwe Kehrel & Kai Klischan & Nathalie Sick, 2016. "Why Research Partnerships Fail in the Biotechnology Sector — An Empirical Analysis of Strategic Partnerships," International Journal of Innovation and Technology Management (IJITM), World Scientific Publishing Co. Pte. Ltd., vol. 13(01), pages 1-23, February.
    14. Charles Baum & Katherine Andino & Eric Wittbrodt & Shelley Stewart & Keith Szymanski & Robin Turpin, 2015. "The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA," PharmacoEconomics, Springer, vol. 33(7), pages 643-653, July.
    15. Wittmann, Nadine, 2014. "Economic reasoning on the correlation between life expectancy and economic development: Exploring alternative routes," Economics Discussion Papers 2014-43, Kiel Institute for the World Economy (IfW Kiel).
    16. Lazonick, William & Tulum, Öner, 2011. "US biopharmaceutical finance and the sustainability of the biotech business model," Research Policy, Elsevier, vol. 40(9), pages 1170-1187.
    17. Michael Schlander & Karla Hernandez-Villafuerte & Chih-Yuan Cheng & Jorge Mestre-Ferrandiz & Michael Baumann, 2021. "How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment," PharmacoEconomics, Springer, vol. 39(11), pages 1243-1269, November.
    18. Veronika Fenyves & Balazs Nyul & Krisztina Dajnoki & Zoltan Bacs & Gergo Tomori, 2019. "Profitability of Pharmaceutical Companies in the Visegrád Countries," Montenegrin Journal of Economics, Economic Laboratory for Transition Research (ELIT), vol. 15(4), pages 99-111.
    19. Tobias Basse & Christoph Schwarzbach & J.-Matthias Schulenburg, 2023. "Dividend policy issues in the European pharmaceutical industry: new empirical evidence," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(5), pages 803-816, July.
    20. Krisztian Buza & Ladislav Peška & Júlia Koller, 2020. "Modified linear regression predicts drug-target interactions accurately," PLOS ONE, Public Library of Science, vol. 15(4), pages 1-18, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:33:y:2015:i:7:p:749-763. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.